Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Clinical studies of BRAF inhibition therapy for recurrent ameloblastoma
| Author | Gender | Age (year) | Metastasis | Drug | Dose | Result |
| Kaye et al. | Male | 40 | (+) | Dabrafenib | 150 mg, twice daily | Notable tumor reduction on
recurrent and metastatic sites |
| Trametinib | 2 mg, once daily | |||||
| Faden et al. | Female | 83 | (–) | Dabrafenib | 75 mg, twice daily | Notable tumor reduction on recurrent site |
